<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENYLEPHRINE HYDROCHLORIDE - phenylephrine hydrochloride solution/ drops </strong><br>Paragon BioTeck, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Phenylephrine Hydrochloride Ophthalmic Solution 2.5% and 10% safely and effectively.  See full prescribing information for Phenylephrine Hydrochloride Ophthalmic Solution 2.5% and 10%<br><span class="Bold">Initial U.S. Approval: </span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil [<a href="#section-2"> 1</a>]. </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>For patients 1 year of age and older, apply one drop of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% or 10% at 3 to 5 minute intervals up to a maximum of 3 drops per eye. [<a href="#a229-0002a5d5c51bjt-2-1">2.1</a>]</li>
<li>In pediatric patients less than 1 year of age, one drop of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be instilled at 3 to 5 minute intervals up to a maximum of 3 drops per eye. [<a href="#a40e-0002a5d5c51bjt-2-2">2.2</a>]</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">2.5% and 10% sterile ophthalmic solutions [<a href="#b3ae-0002a5d5c51bjt-3">3</a>].
								 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [<a href="#aae348a0-f065-11e0jt-4-1">4.1</a>]</li>
<li>Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [<a href="#a13e-0002a5d5c51bjt-4-2">4.2</a>]</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Not for injection. Topical ophthalmic use only [<a href="#a203-0002a5d5c51bjt-5-1">5.1</a>]</li>
<li>Reports of serious cardiovascular reactions, some fatal, with phenylephrine hydrochloride 10% solution. Monitor blood pressure in patients with cardiovascular disease [<a href="#aabc-0002a5d5c51bjt-5-2">5.2</a>]</li>
<li>Significant elevations in blood pressure have been reported. Caution in pediatric patients less than 5 years of age, and in patients with elevated blood pressure [<a href="#a1e6-0002a5d5c51bjt-5-3">5.3</a>].</li>
<li>Rebound <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> has been reported one day after instillation [<a href="#b69e-0002a5d5c51bjt-5-4">5.4</a>]</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Ocular adverse reactions include <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> on instillation, temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> [<a href="#bbaf-0002a5d5c51bjt-6-1">6.1</a>].</li>
<li>Cardiovascular adverse reactions include increase in blood pressure, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> and <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> [<a href="#bdd4-0002a5d5c51bjt-6-2">6.2</a>].</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Paragon BioTeck, Inc. at 1-888-424-1192 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>May exaggerate the adrenergic pressor response in patients taking atropine-like drugs [<a href="#a297-0002a5d5c51bjt-7-1">7.1</a>]</li>
<li>May potentiate the cardiovascular depressant effects of potent inhalation anesthetic agents [<a href="#a297-0002a5d5c51bjt-7-1">7.1</a>]</li>
</ul></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	General Dosing Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Pediatric Patients Less Than 1 Year of Age</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	Cardiac and Endocrine Disease</a></h2>
<h2><a href="#section-4.2" class="toc">4.2	Pediatric Patients Less Than 1 Year of Age</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Topical Ophthalmic Use Only</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Cardiovascular Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Elevation in Blood Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Rebound <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Ocular Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Systemic Adverse Reactions</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Agents That May Exaggerate Pressor Responses</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10.	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2.	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b3b188e0-f063-11e0jt-1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% and 10% is indicated to dilate the pupil.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a0a5-0002a5d5c51bjt-2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a00d-0002a5d5c51bjt-2-1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	General Dosing Recommendations</h2>
<p class="First">In patients 1 year of age or greater, apply one drop of either Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops. If necessary, this dose may be repeated.</p>
<p>In order to obtain a greater degree of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% may be needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a229-0002a5d5c51bjt-2-2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Pediatric Patients Less Than 1 Year of Age</h2>
<p class="First">In pediatric patients less than 1 year of age, one drop of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be instilled at 3 to 5 minute intervals up to a maximum of 3 drops per eye.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="b3ae-0002a5d5c51bjt-3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% is a clear, colorless, sterile topical ophthalmic solution containing phenylephrine hydrochloride 2.5%.</p>
<p>Phenylephrine Hydrochloride Ophthalmic Solution, 10% is a clear, colorless, sterile topical ophthalmic solution containing phenylephrine hydrochloride 10%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bc6a-0002a5d5c51bjt-4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="aae348a0-f065-11e0jt-4-1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	Cardiac and Endocrine Disease</h2>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>.  Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a13e-0002a5d5c51bjt-4-2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	Pediatric Patients Less Than 1 Year of Age</h2>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients <span class="Italics">[See <a href="#a0a5-0002a5d5c51bjt-2">Dosage and Administration section</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b6cd-0002a5d5c51bjt-5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a203-0002a5d5c51bjt-5-1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Topical Ophthalmic Use Only</h2>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% and 10% is not indicated for injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="aabc-0002a5d5c51bjt-5-2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Cardiovascular Reactions</h2>
<p class="First">There have been reports of serious cardiovascular reactions, including <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>, in patients using phenylephrine 10%. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a1e6-0002a5d5c51bjt-5-3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Elevation in Blood Pressure</h2>
<p class="First">A significant elevation in blood pressure is not common but has been reported following conjunctival instillation of recommended doses of phenylephrine 10%. The risk is less with phenylephrine 2.5%. Caution should be exercised with the use of phenylephrine 10% in pediatric patients less than 5 years of age and patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, or cardiovascular disease. The post-treatment blood pressure of patients with cardiac and endocrine diseases and any patients who develop symptoms should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b69e-0002a5d5c51bjt-5-4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Rebound <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span></h2>
<p class="First">Rebound <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> has been reported one day after receiving phenylephrine hydrochloride ophthalmic solution, and re instillation of the drug produced a lesser mydriatic effect.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a0f5-0002a5d5c51bjt-6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:
						
						•	Cardiac Disease <span class="Italics">[See <a href="#aabc-0002a5d5c51bjt-5-2">Warnings and Precautions (5.2)</a>]</span>
						•	Elevation in Blood Pressure <span class="Italics">[See <a href="#a1e6-0002a5d5c51bjt-5-3">Warnings and Precautions (5.3)</a>]</span>
						
						The following adverse reactions have been identified following use of phenylephrine hydrochloride ophthalmic solution.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
					</p>
<div class="Section" data-sectionCode="42229-5">
<a name="bbaf-0002a5d5c51bjt-6-1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Ocular Adverse Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> on instillation, temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and conjunctival sensitization may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bdd4-0002a5d5c51bjt-6-2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Systemic Adverse Reactions</h2>
<p class="First">A marked increase in blood pressure has been reported particularly, but not limited to <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">low weight</span> premature neonates, infants and hypertensive patients. </p>
<p>Cardiovascular reactions which have occurred primarily in hypertensive patients following topical ocular use of phenylephrine hydrochloride ophthalmic solution 10% solution include marked increase in blood pressure, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> and <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. <span class="Italics">[See <a href="#aabc-0002a5d5c51bjt-5-2">Warnings and Precautions (5.2</a> and <a href="#a1e6-0002a5d5c51bjt-5-3">5.3)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="beaa-0002a5d5c51bjt-7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a297-0002a5d5c51bjt-7-1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Agents That May Exaggerate Pressor Responses</h2>
<p class="First">Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> in some patients.

	Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="aa79e960-f06e-11e0jt-8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ada4-0002a5d5c51bjt-8-1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Pregnancy Category C: Animal reproduction studies have not been conducted with topical phenylephrine.  It is also not 
known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ae67-0002a5d5c51bjt-8-3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% and 10% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ae2a-0002a5d5c51b-8-4"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, 10% is contraindicated in pediatric patients less than 1 year of ageinfants. Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% should be used in these patients <span class="Italics">[See <a href="#b56e-0002a5d5c51bjt-4-2">4.2 Contraindications</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="a2ee-0002a5d5c51bjt-8-5"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">No overall differences in safety and effectiveness have been observed between elderly and younger adult patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="a283-0002a5d5c51bjt-10"></a><a name="section-9"></a><p></p>
<h1>10.	OVERDOSAGE</h1>
<p class="First">Overdosage of phenylephrine may cause a rapid <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>. It may also cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Prompt injection of a rapidly acting alpha-adrenergic blocking agent such as phentolamine has been recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="bb01-0002a5d5c51bjt-11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is a sterile, clear, colorless, topical mydriatic agent for ophthalmic use. The chemical name is (R)-3-hydroxy-α-[(methylamino)methyl]benzenemethanol hydrochloride. Phenylephrine hydrochloride is represented by the following structural formula:</p>
<p><img alt="Phenylephrine hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4d3fe20-f063-11e0-ac29-0002a5d5c51b&amp;name=phenylephrine-hydrochloride-figure-1.jpg"></p>
<p>Phenylephrine hydrochloride has a molecular weight of 203.67 and an empirical formula of C<span class="Sub">9</span>H<span class="Sub">13</span>NO<span class="Sub">2</span>-HCl.</p>
<p>Each mL of Phenylephrine Hydrochloride Ophthalmic Solution, 2.5% contains: ACTIVE: phenylephrine hydrochloride 25 mg (2.5%); INACTIVES: sodium phosphate monobasic, sodium phosphate dibasic; boric acid, water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.0-6.4). The solution has a tonicity of 500 mOsm/kg. PRESERVATIVE: benzalkonium chloride 0.01%.</p>
<p>Each mL of Phenylephrine Hydrochloride Ophthalmic Solution, 10% contains: ACTIVE: phenylephrine hydrochloride 100 mg (10.0%); INACTIVES: sodium phosphate monobasic, sodium phosphate dibasic; water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.3-6.7). The solution has a tonicity of 1000 mOsm/kg. PRESERVATIVE: benzalkonium chloride 0.01%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a8d6-0002a5d5c51bjt-12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ac65-0002a5d5c51bjt-12-1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Phenylephrine is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels and the radial muscle of the iris.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="b86f-0002a5d5c51bjt-12-2"></a><a name="section-11.2"></a><p></p>
<h2>12.2.	Pharmacodynamics</h2>
<p class="First">Maximal <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> occurs in 20 to 90 minutes with recovery after 3 to 8 hours.</p>
<p>Systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic effects, such as <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> which may be accompanied by a reflex atropine-sensitive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="a6bf-0002a5d5c51bjt-12-3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The systemic exposure following topical administration of phenylephrine hydrochloride ophthalmic solution has not been studied. A higher systemic absorption is expected for the 10% solution than the 2.5% solution and when the corneal barrier function is compromised. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ba1a-0002a5d5c51bjt-14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Pupillary dilation following topical administration of phenylephrine hydrochloride ophthalmic solution has been demonstrated in controlled clinical studies in adults and pediatric patients with different levels of iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>.  Pupil movement is generally seen within 15 minutes, maximal <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> between 20 to 90 minutes and recovery after 3 to 8 hours.  Darker irides tend to dilate slower than lighter irides<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d2dc3d80-f06f-11e0jt-16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% is supplied as a sterile, aqueous, topical ophthalmic solution  with a fill volume of 15 mL in a 15 mL opaque, white low density polyethylene (LDPE) bottle with a linear low density polyethylene (LLDPE) dropper tip and red cap. (NDC 42702-102-15)<br></p>
<p>Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is supplied as a sterile, aqueous, topical ophthalmic solution  with a fill volume of 5 mL in a 10 mL opaque, white LDPE bottle with a LLDPE dropper tip and red cap. (NDC 42702-103-05) </p>
<div class="Section" data-sectionCode="44425-7">
<a name="a41d-0002a5d5c51bjt-16-1"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span></p>
<p>Store in a refrigerator at 2° to 8°C (36°-46°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="e36b21c0-f06f-11e0jt-17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients not to touch the dropper tip to any surface as this may contaminate the solution.</p>
<p>Inform patients they may experience sensitivity to light and should protect their eyes in bright illumination while their pupils are dilated.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bde3-0002a5d5c51b-plp-1"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Phenylephrine Hydrochloride Ophthalmic Solution - 2.5% 15 mL Bottle Label</span></p>
<p><img alt="Phenylephrine Hydrochloride Ophthalmic Solution - 2.5% 15 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4d3fe20-f063-11e0-ac29-0002a5d5c51b&amp;name=phenylephrine-hydrochloride-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bde3-0002a5d5c51b-plp-2"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Phenylephrine Hydrochloride Ophthalmic Solution - 2.5% 15 mL Bottle Carton</span></p>
<p><img alt="Phenylephrine Hydrochloride Ophthalmic Solution - 2.5% 15 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4d3fe20-f063-11e0-ac29-0002a5d5c51b&amp;name=phenylephrine-hydrochloride-figure-3.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bde3-0002a5d5c51b-plp-3"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Phenylephrine Hydrochloride Ophthalmic Solution - 10% 5 mL Bottle Label</span></p>
<p><img alt="Phenylephrine Hydrochloride Ophthalmic Solution - 10% 5 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4d3fe20-f063-11e0-ac29-0002a5d5c51b&amp;name=phenylephrine-hydrochloride-figure-4.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bde3-0002a5d5c51b-plp-4"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Phenylephrine Hydrochloride Ophthalmic Solution - 10% 5 mL Bottle Carton</span></p>
<p><img alt="Phenylephrine Hydrochloride Ophthalmic Solution - 10% 5 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4d3fe20-f063-11e0-ac29-0002a5d5c51b&amp;name=phenylephrine-hydrochloride-figure-5.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENYLEPHRINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">phenylephrine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42702-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>phenylephrine hydrochloride</strong> (phenylephrine) </td>
<td class="formItem">phenylephrine hydrochloride</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>boric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42702-102-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203510</td>
<td class="formItem">04/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENYLEPHRINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">phenylephrine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42702-103</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>phenylephrine hydrochloride</strong> (phenylephrine) </td>
<td class="formItem">phenylephrine hydrochloride</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>boric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42702-103-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203510</td>
<td class="formItem">04/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Paragon BioTeck, Inc.
							(078279037)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Paragon BioTeck, Inc. (078279037)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ff4531e8-5933-4524-bf23-fb7a5e0fc2f5</div>
<div>Set id: a4d3fe20-f063-11e0-ac29-0002a5d5c51b</div>
<div>Version: 2</div>
<div>Effective Time: 20130320</div>
</div>
</div> <div class="DistributorName">Paragon BioTeck, Inc.</div></p>
</body></html>
